stockrowTango Therapeutics, Inc.
TNGX Healthcare Biotechnology
Tango Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.4 million, up 48.3% from fiscal 2024.
- Revenue
- −100.0%
- EPS
- −5.71%
- Free cash flow
- −4.58%
Quarter to June 2026, against a year earlier
Follow TNGX
Alert me
Tango Therapeutics, Inc. (TNGX) Book value per share
Tango Therapeutics, Inc.'s book value per share at the end of fiscal 2025 was 3.0×, up 63.1% from 1.8× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 6.8×. Over the past ten years it has ranged from 1.2× (fiscal 2020) to 5.6× (fiscal 2021); the current reading is higher than 83% of that period. Tango Therapeutics, Inc. ranks 116th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 3.0× | 63.14% |
| FY2024 | 1.8× | (31.75%) |
| FY2023 | 2.7× | (5.79%) |
| FY2022 | 2.8× | (48.82%) |
| FY2021 | 5.6× | 359.20% |
| FY2020 | 1.2× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 6.8× | 150.69% |
| Mar 2026 | 2.7× | (8.50%) |
| Dec 2025 | 3.0× | 106.63% |
| Sep 2025 | 1.4× | 18.13% |
| 21 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| PBLS Parabilis Medicines, Inc. compare | 36.2× |
| IRON Disc Medicine, Inc. compare | 16.7× |
| XENE Xenon Pharmaceuticals Inc. compare | 12.5× |
| ACAD ACADIA Pharmaceuticals Inc. compare | 8.0× |
| TNGX Tango Therapeutics, Inc. | 6.8× |
| RLAY Relay Therapeutics, Inc. compare | 4.4× |
| EWTX Edgewise Therapeutics, Inc. compare | 4.2× |
| ABCL AbCellera Biologics Inc. compare | 2.9× |
| IOVA Iovance Biotherapeutics, Inc. compare | 0.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on TNGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement